SCHEMBL9470689

SCHEMBL9470689

FC(F)c1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
TSHR P16473 2/20 0.50
MAPK1 P28482 2/20 0.50
HIF1A Q16665 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
CYP2A6 P11509 1/20 0.50
TP53 P04637 1/20 0.48
HPGD P15428 1/20 0.48
ADRB2 P07550 1/20 0.48
CYP19A1 P11511 5/20 0.44
IDO1 P14902 4/20 0.44
TDO2 P48775 3/20 0.44
TRPV4 Q9HBA0 1/20 0.40
BRD4 O60885 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL662302 0.83 PGK1 (0.38) IDO1TDO2TRPV4
SCHEMBL17816190 0.81 TSHR (0.50) LMNATSHRMAPK1HIF1ATDP1
Bromide SCHEMBL9813321 0.79 NOTUM (0.37) TRPV4
SCHEMBL29066009 0.77 TSHR (0.46) LMNATSHRMAPK1HIF1ATDP1
SCHEMBL29200286 0.77 TSHR (0.46) LMNATSHRMAPK1HIF1ATDP1
SCHEMBL16425762 0.77 ADRB2 (0.56) LMNATSHRMAPK1HIF1ATDP1
SCHEMBL21994332 0.77 TSHR (0.46) LMNATSHRMAPK1HIF1ATDP1
SCHEMBL4547938 0.75 TYR (0.46) LMNAMAPK1HIF1AHPGDADRB2
SCHEMBL14501582 0.75 TRPV4 (0.35) TSHRMAPK1HIF1ATDP1TRPV4
SCHEMBL14501581 0.75 TSHR (0.50) TSHRMAPK1HIF1ATDP1TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113185473-B Preparation method of florfenicol intermediate fluoromethylsulfone oxazole 山东国邦药业有限公司 2021-10-08 CN claimed
CN-113185473-A Preparation method of florfenicol intermediate fluoromethylsulfone oxazole 山东国邦药业有限公司 2021-07-30 CN claimed
EP-3089980-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2018-01-31 EP claimed
US-9670208-B2 Serine/threonine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-06-06 US claimed
EP-3089980-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-11-09 EP claimed
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-10-20 US claimed
WO-2015103137-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-07-09 WO claimed
EP-3632892-B1 METHOD FOR PRODUCING 3-ARYLPROPIONAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2024-07-31 EP disclosed
CN-110799490-B 3-arylpropionamide compound and method for producing 3-arylpropionate compound 住友化学株式会社 2023-05-02 CN disclosed
US-11376260-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2022-07-05 US disclosed
CN-113185473-B Preparation method of florfenicol intermediate fluoromethylsulfone oxazole 山东国邦药业有限公司 2021-10-08 CN disclosed
CN-113185473-B Preparation method of florfenicol intermediate fluoromethylsulfone oxazole 山东国邦药业有限公司 2021-10-08 CN disclosed
CN-113185473-A Preparation method of florfenicol intermediate fluoromethylsulfone oxazole 山东国邦药业有限公司 2021-07-30 CN disclosed
CN-101238602-A Electrode electrolyte for use in solid polymer fuel cell JSR CORP (JP) 2008-08-06 CN disclosed
CN-101223208-A Nitrogenated aromatic compound, process for production of the same, polymer, and proton conductive membrane JSR CORP (JP) 2008-07-16 CN disclosed
CN-1981352-A Electrochemical capacitor JSR CORP (JP) 2007-06-13 CN disclosed
US-5233105-A Fluorination using hydrogen fluoride BAYER AKTIENGESELLSCHAFT (DE) 1993-08-03 US disclosed
EP-0425887-A2 Process for halogen-fluor exchange in organic compounds and catalysts therefor BAYER AG (DE) 1991-05-08 EP disclosed
EP-0076718-B1 PROCESS FOR THE HALOGENATION OF METADIHALOGENOBENZENES RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1984-09-12 EP disclosed
EP-0076718-A1 Process for the halogenation of metadihalogenobenzenes RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1983-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376260-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 LMNA 2948/4885TSHR 2044/4885MAPK1 12/4885
US-20160304519-A1 SERINE/THREONINE KINASE INHIBITORS TTBK1, MAP3K1, TNNI3K LMNA 1573/4885TSHR 2352/4885MAPK1 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.